SARomics Biostructures, University of Copenhagen and Enamine join forces to develop the next generation of safer anti-depressants

SARomics Biostructures, University of Copenhagen and Enamine join forces to develop the next generation of safer anti-depressants

Depression is one of the most common mental illnesses. The WHO lists depression as one of the most debilitating conditions in the world, with severe depression rated in the same disability category as terminal stage cancer. Unfortunately, current antidepressant treatments fail to alleviate the suffering of up to 30% of the affected patients.

Backed by a EU grant of 1.3 mEuro, the newly establish Marie Curie industrial doctorate training network SAFER will strive to identify functionally Selective Agonists For the 5-HT2A Serotonin Receptor and thus provide novel tools dissecting serotonin signaling within the brain. This will guide the discovery novel chemical entities, which eventually will provide more effective and safe drugs for the treatment of depression.

SAFER is now recruiting 5 PhD students to work within pharmacology, medicinal chemistry, crystallography, computational drug design and scientific database development.

For more information about the project and the available positions, see http://www.safer-itn.eu/

SARomics Biostructures AB